GlassScriptPhysician profile
Miranda Meadows
NPI 1821736893
$1,752.53
in general payments reported to CMS, 2019-2025
26 companies · $701 in 2025
The $701 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.55 · 2023: $518 · 2024: $510 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,663 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,662.99 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $449.85 | 2023-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $242.68 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $168.15 | 2023-2025 | |
| Axsome Therapeutics, INC. | $139.96 | 2025 | Auvelity |
| Lilly USA, LLC | $133.56 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Vanda Pharmaceuticals INC. | $111.72 | 2025 | Fanapt |
| Pfizer INC. | $63.16 | 2024-2025 | |
| Glaxosmithkline, LLC. | $48.22 | 2024-2025 | Trelegy Ellipta |
| Mylan Specialty L.P. | $43.01 | 2023-2024 | Yupelri |
| Novo Nordisk INC | $36.66 | 2023 | Wegovy, Saxenda |
| Corcept Therapeutics | $34.15 | 2024 | Korlym |
| Sage Therapeutics, LLC | $33.60 | 2024-2025 | Zurzuvae |
| Biohaven Pharmaceutical Holding Company LTD. | $23.55 | 2022 | |
| Horizon Therapeutics Plc | $21.91 | 2023 | Krystexxa |
| Inspire Medical Systems, INC. | $20.12 | 2025 | Inspire |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $20.06 | 2025 | Aptima |
| Daiichi Sankyo INC. | $19.83 | 2024 | Injectafer |
| Agile Therapeutics, INC. | $18.48 | 2024 | Twirla |
| Organon LLC | $18.01 | 2025 | Nexplanon |
| Xeris Pharmaceuticals, INC. | $17.29 | 2025 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $16.36 | 2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $15.76 | 2025 | Uzedy |
| Sumitomo Pharma America, INC. | $14.68 | 2024 | Myfembree |
| Merck Sharp & Dohme LLC | $14.36 | 2025 | Vaxneuvance, Enflonsia, Rotateq |
| Abbott Laboratories | $13.72 | 2025 | Freestyle Libre 3 |
| Nestle Healthcare Nutrition INC. | $13.68 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Meadows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.